|âABLE- DBTÂ partnershipÂ encouragesÂ entrepreneurÂ workshop andÂ judge businessÂ plans of the nextÂ generation toÂ provide the bestÂ to the biotechÂ industryâ|
KiranÂ shares her thought in a tÃªte-a-tÃªteÂ with Shally Makin, ENN on the initiatives in the Biotechnology sector. SheÂ believes that we should be led by science and not by activism.
Being the Founding President ofÂ ABLE, with what vision you hadÂ brought this association intoÂ action?
ABLE is a not-for-profit pan-India forumÂ that represents the Indian BiotechnologyÂ Sector. It was launched inÂ April 2003, after industry leaders feltÂ a need to form an exclusive forum toÂ represent the Indian BiotechnologyÂ Sector. It has over 270 members fromÂ all across India representing all verticalsÂ of the sector like agri biotech, biopharma,Â industrial biotech, bioinformatics,Â investment banks and centureÂ capital firms, leading research andÂ academic institutes and law firms andÂ equipment suppliers.
What initiatives have ABLEÂ worked towards the sector overÂ the past decade?
ABLE has initiated to accelerateÂ the pace of growth of the BiotechnologyÂ sector in India, throughÂ partnering with the Government inÂ their biotechnology initiatives toÂ deliver optimal policies and createÂ a positive regulatory environment,Â encouraging entrepreneurship andÂ investment in the sector, providing aÂ platform for domestic and overseasÂ companies to explore collaborationÂ and partnerships, we were able toÂ catalyse regulatory reforms, forgingÂ stronger links between academiaÂ and industry and showcasing theÂ strengths of the Indian biotech sector.Â ABLE has focused on regulatoryÂ issues, training programmes,Â connecting with media and investorÂ community to understand the opportunitiesÂ to invest in this sector.Â ABLE- DBT partnership encouragesÂ entrepreneur workshop and judgeÂ business plans of the next generationÂ to provide the best to the biotechÂ industry. We hold educationalÂ workshops and conferences, tryingÂ to build this potential bio economyÂ to a huge size and shape through innovativeÂ ways of thinking.
Can you highlight theÂ achievements ABLE has in itsÂ flag to vouch about?
Some of the milestones that ABLEÂ has achieved are those related to DrÂ Mashelkar Committee report on recombinantÂ product, Innovative programsÂ of the DST viz. BIRAP andÂ BIPP, Vision document for the IndianÂ Biotech industry, Roadmap for the biotechÂ Industry, building the BiotechnologyÂ Entrepreneurship StudentsÂ team (BEST) and North East LifeÂ Science Entrepreneurship (NEST)Â programs, the BioInvest Program andÂ the International promotion of BrandÂ India through organizing the IndiaÂ Pavilion in various BIO Shows. For aÂ long time, our pharma products wereÂ approved by the âGenetic EngineeringÂ Approving Committeeâ, it should.
|Woman of Substance
A successful technocrat of globalÂ standing, Kiran Mazumbdar ShawÂ heads Indiaâs leading BiotechnologyÂ enterprise, Biocon. Her pioneeringÂ efforts in biotechnology have drawnÂ global recognition both for IndianÂ Industry and Biocon. She presentlyÂ serves on the Advisory Council ofÂ the Governmentâs Department ofÂ Biotechnology where she has beenÂ instrumental in bringing government,Â industry and academia together, toÂ chart a clear and progressive growthÂ path for Biotechnology in India. KiranÂ Mazumbdar Shaw is the recipient ofÂ several prestigious awards includingÂ the most cherished awards -nationalÂ awards, Padmashri (1989) and PadmaÂ Bhushan (2005) presented to her by theÂ President of India, for her pioneeringÂ efforts in Industrial Biotechnology.Â Under her stewardship, Biocon hasÂ evolved from its inception in 1978 as anÂ industrial enzymes company to a fullyÂ integrated Biopharmaceutical enterpriseÂ encompassing a well balanced businessÂ portfolio of products and services withÂ a research focus on Diabetes, OncologyÂ and Auto-immune disease. Her businessÂ Biocon, worth USD 800million, is oneÂ of Indiaâs leading drug companies andÂ employs more than 6,000 people at itsÂ vast campus in Bangalore.
not be an environmental issue and soÂ was brought under DCGI for being aÂ healthcare issue solely. We broughtÂ out a number of white papers, biosimilarÂ guidelines are now developed forÂ the industry by us. ABLE has taken aÂ huge initiative in educating the importanceÂ of genetically modified crop inÂ agribio sector.
How do you foresee theÂ biotechnology sector throughÂ your eyes?
We want some pharma companies toÂ be part of this association and addÂ knowledge to the members of theÂ group. We will keep working towardsÂ improving and addressing regulatory
challenges and works on how toÂ deliver it efficiently. We need to lookÂ at inherent challenges, as the investmentÂ pay back is very long in thisÂ sector unlike others. The inherentÂ gestational timeline gives you a veryÂ long term investment but with anÂ exponential return. Itâs about creatingÂ the right skills and training intoÂ the next generation entrepreneursÂ which includes a lot stakeholdersÂ starting from farmers, scientists,Â and engineers and technology innovators.Â We should also focus on theÂ large natural advantages that weÂ have and convert focus on these innovationsÂ which can help us to scaleÂ globally. I believe after biotechnology,Â India should look for opportunity inÂ genomics and bio IT.
Â About Biocon
Manufacturing is another neglectedÂ sector with an economicÂ model that is much skewed and onlyÂ contributes 15 percent in the GDP.
This offers employment opportunities,Â as we being the largest vaccineÂ manufacturers, largest manufacturersÂ in generic drugs, we need to findÂ answers if we can repeat the historyÂ in being the largest manufacturers inÂ biologics. Can we go beyond genericÂ vaccines, DNA vaccines is what I seeÂ the future to creep into the biotechnologyÂ sector